Review Article

Drug Resistance in Visceral Leishmaniasis

Helena C. Maltezou

Department for Interventions in Health-Care Facilities, Hellenic Center for Disease Control and Prevention, 15123 Athens, Greece

Correspondence should be addressed to Helena C. Maltezou, helen-maltezou@ath.forthnet.gr

Received 29 June 2009; Revised 10 August 2009; Accepted 30 August 2009

Academic Editor: Abhay R. Satoskar

Copyright © 2010 Helena C. Maltezou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Visceral leishmaniasis remains a public health problem worldwide. This illness was included by the World Health Organization in the list of neglected tropical diseases targeted for elimination by 2015. The widespread emergence of resistance to pentavalent antimonials in India where half cases occur globally and the unavailability of a vaccine in clinical use constitute major obstacles in achieving this goal. The last decade new antileishmanials became available, including the oral agent miltefosine. However, in poor endemic countries their wide use was curtailed because of the high costs, and also due to concerns of toxicity and emergence of resistance. Various mechanisms of antileishmanial resistance were identified recently in field isolates. Their elucidation will boost the design of new drugs and the molecular surveillance of resistance. Combination regimens should be evaluated in large trials. Overall, the development of antileishmanials has been generally slow; new drugs are needed. In order to control visceral leishmaniasis worldwide, treatment advances should become affordable in the poorest countries, where they are needed most.

1. Introduction

Visceral leishmaniasis (VL; also known as kala azar) is a protozoan systemic infection, which is almost always fatal if left untreated. This illness is endemic in several tropical and subtropical regions and in the Mediterranean basin. The estimated annual global burden of VL is 500,000 new cases and more than 50,000 deaths, of which 90% occur just in five countries—India, Bangladesh, Nepal, Sudan, and Brazil [1]. VL is transmitted through hematophagous sandflies and is caused by Leishmania donovani in the Indian subcontinent, Asia, and Africa, L. infantum in the Mediterranean basin, and L. chagasi in South America. After an incubation period of several months, typical VL manifests with intermittent fever, weight loss, massive hepatosplenomegaly, and progressive deterioration of the host; hemorrhages and edemas may develop late in the course [2–4]. Leishmaniasis was selected by the World Health Organization for elimination by 2015, along with other neglected tropical diseases [5]. Since there is no antileishmanial vaccine in clinical use, control of VL relies almost exclusively on chemotherapy.

For almost seven decades pentavalent antimonials constituted the standard antileishmanial treatment worldwide, however the last 15 years their clinical value was jeopardized due to the widespread emergence of resistance to these agents in Bihar, India, where half of VL cases occur globally [6]. The last decade novel formulations of conventional antileishmanials as well as new drugs, including the oral agent miltefosine, became available or are under investigation. In practice, however, their wide use in poor countries is hampered mainly due to high costs and also due to concerns of toxicity and emergence of resistance [6]. In response to concerns about preserving the currently available antileishmanials, especially in regions with anthropic parasite transmission, there is growing interest on combination regimens. Control of VL in poor countries is further compromised by the emergence of human immunodeficiency virus (HIV)-VL-coinfection [7]. This article will review recent publications on antileishmanial drugs, with emphasis on resistance issues. Strategies to preserve the activity of currently available drugs will be addressed.

2. Pathogenesis and Immune Response

Leishmanias are obligatory intracellular protozoan parasites. The parasites remain within their vectors as extracellular promastigotes [8]. Following sandfly bite, neutrophils migrate...
locally and capture the parasites, however the latter have the ability to escape and subsequently invade the macrophages of the skin, where they differentiate and replicate as amastigotes [9, 10]. From there, parasites disseminate and invade additional macrophages of the reticuloendothelial system, and finally infiltrate the bone marrow, liver, and spleen [8]. VL should be regarded as a state of long-term parasitism, since leishmanias are not eradicated completely but rather remain in skin macrophages for lifetime, even after successful treatment in hosts with intact T-cell immune responses. In skin, leishmanias act as a reservoir for the potential relapse of symptomatic VL. The risk for relapse increases when T-cell immune responses are impaired and irrespectively of prior antileishmanial treatment, as noted in HIV-infected patients [7, 11, 12]. Relapses usually peak 6–12 months after treatment.

Following Leishmania infection, host immune responses are elicited. Immune responses are characterized by a mixed T-helper cell-type 1 (Th1) and Th2 response, the production of cytokines, and the activation of macrophages [13–15]. High levels of specific antibodies are also detected however their exact role remains unclear [8]. Recent evidence indicates that the first weeks following infection, neutrophils play a significant role in the killing of parasites and the development of a protective Th1 immune response [9, 10].

The immunologic mechanisms that underlie the resolution of infection or the progression and systemic dissemination of leishmanias have not been elucidated completely so far. Following infection, T-cell-dependent immune responses are elicited in an integrated fashion. Interleukin 12 (IL12) promotes cell-mediated immunity. Activated CD4 T cells are recruited to cutaneous or visceral sites of infection and direct the local inflammatory responses. CD4 T-cell responses are associated with the interferon (IFN)-γ-induced macrophage activation through participation of cytokines, mainly IL12 and also IL2 and tumor necrosis factor, and the intracellular parasite killing by activated macrophages [8]. IL4 also plays an important role in effective antileishmanial chemotherapy, which appears to be modulated by IFN-γ-production [16]. Deactivation of macrophages, suppression of Th1 responses, and dissemination of leishmanial infection are induced by IL10 [14]. Increased IL10 levels have been detected repeatedly in human VL and are considered crucial in uncontrolled leishmanial infection [13, 14]. Targeting IL10 has been associated with activation of Th1 responses and parasite killing, whereas IL10 suppression constituted a critical step in vaccine-mediated immunotherapy [17]. Most data on cellular immune responses and cytokines have been observed in murine models; similar results have been found in humans.

3. Antimonials

Although pentavalent antimonials (meglumine antimoniate and sodium stibogluconate) are in clinical use for several decades, there are aspects on their mechanism of action that remain unclear. It is generally accepted that pentavalent antimonials (SbV) are the prodrug, and that they should convert to trivalent antimonials (SbIII) in order to demonstrate their antileishmanial activity [18–20]. Recent evidence indicates that antimonials kill leishmanias by a process of apoptosis [20]. Thioli metabolism is critical in their mechanism of action. Trypanothione is the major thiol in leishmanias. SbIII inhibits trypanothione reductase in vitro, inducing the loss of intracellular thiols and a lethal imbalance in thiol homeostasis, leading to accumulation of reactive oxygen species [20–22]. In order for antimonials to exert their action, an almost intact immune system of the host is required.

Initially antimonials were given at 10 mg/kg for 6–10 days with >90% cure rates, however after the first treatment failures occurred in India two decades ago, higher doses and prolonged schemes (up to 20 mg/kg for 30 days) were introduced gradually and in parallel with the increasing rates of antimony unresponsiveness [23]. However, the dose escalation policy did not prevent further emergence of resistance, but rather selected resistant parasites. During the last decade, antimonial resistance and therapeutic failures reached epidemic dimensions in Bihar, India; nowadays, up to 60% of newly diagnosed VL cases in this area do not respond to antimonials [23]. Inadequate treatment in terms of dosing and duration, and poor compliance promote the widespread antimonial resistance in India. In this country, the high incidence rate of unresponsiveness to antimonials is further sustained by the anthropoontic transmission of leishmanial infection, which increases the chances for the rapid spread of resistant parasites among humans once they emerge [24, 25]. Low rates of antimonial resistance have been reported in Sudan also [26]. Pentavalent antimonials were abandoned in India, however they remain the first treatment choice in most VL-endemic areas in the rest of the world, with efficacy rates exceeding 90%–95% and low case fatality and relapse rates [2–4, 27]. Low cost is their main advantage. Disadvantages include intramuscular administration, prolonged treatment, and transient, but occasionally life-threatening adverse effects, such as cardiac arrhythmias, increased hepatic transaminases, pancreatitis, and pneumonia [2–4, 23].

While several experimental studies on antimonial resistance have been conducted with parasite mutants selected in vitro using step-wise increasing drug concentrations, resistance mechanisms in field parasites have not been elucidated in details. Mechanisms of in vitro antimonial resistance may differ from mechanisms in field isolates [28]. Similarly, in vitro unresponsiveness does not necessarily translate to clinical resistance [29]. Reduction of drug concentration within the parasite, either by decreasing drug uptake or by increasing efflux/sequestration of the drug, constitutes the primary mechanism of antimonial resistance; other potential resistance mechanisms include inhibition of drug activation, inactivation of active drug, and gene amplification [18, 20, 28, 30–32].

Thiol metabolism possesses a key role in both clinical and laboratory-generated resistance mechanisms. It has been found that elevated intracellular thiol levels and overexpression of tryparodoxin peroxidase are associated with high levels of SbIII resistance [22, 31, 33]. However, it appears that
more than one step in thiol metabolism should be impaired in order for resistance to emerge, indicating that antimonial resistance is multifactorial. In natural antimonial resistance, the impaired thiol metabolism results in inhibition of SbV activation and decreased uptake of the active form SbIII by amastigotes; these processes are accomplished by the activation and decreased uptake of the active form SbIII in order for resistance to emerge, indicating that antimonial more than one step in thiol metabolism should be impaired during repeated VL episodes (mean follow-up period: 35.6 months; range: 3–137 months), despite repeated courses of amphotericin B; these data indicate that amphotericin B will remain a very useful drug for the treatment or secondary prophylaxis in this group of patients, even after repeated use [11].

The routine scheme of conventional amphotericin B is 1/mg/kg administered on alternate days for a total of 30 days; however, a recent study in India showed 96% cure rates with a dose of 0.75 mg/kg/day for 15 days [6]. Major disadvantages of conventional amphotericin B are its prolonged administration and the frequent adverse effects, such as infusion-related fever and chills, nephrotoxicity, and hypokalemia, which necessitate administration in hospital [6]. Conventional amphotericin B is used exclusively in India for cases unresponsive to antimonials or even as a first line drug. However, outside India this drug does not offer any advantage over pentavalent antimonials.

4. Amphotericin-B and Its Lipid Formulations

Conventional amphotericin B has been used as a second-line treatment for VL since the 1960s. This drug exhibits an excellent antileishmanial activity with >90%-95% cure rates in Indian VL cases. Unresponsiveness and relapses occur rarely, except among HIV-infected patients [3, 11, 12]. In this population, secondary episodes of VL are common and are attributed mainly to relapse but also to reinfection [11]. A recent study failed to disclose decreased susceptibility among leishmanias collected from HIV-infected patients during repeated VL episodes (mean follow-up period: 35.6 months; range: 3–137 months), despite repeated courses of amphotericin B; these data indicate that amphotericin B will remain a very useful drug for the treatment or secondary prophylaxis in this group of patients, even after repeated use [11].

The routine scheme of conventional amphotericin B is 1/mg/kg administered on alternate days for a total of 30 days; however, a recent study in India showed 96% cure rates with a dose of 0.75 mg/kg/day for 15 days [6]. Major disadvantages of conventional amphotericin B are its prolonged administration and the frequent adverse effects, such as infusion-related fever and chills, nephrotoxicity, and hypokalemia, which necessitate administration in hospital [6]. Conventional amphotericin B is used exclusively in India for cases unresponsive to antimonials or even as a first line drug. However, outside India this drug does not offer any advantage over pentavalent antimonials.

Lipid formulations of amphotericin B improved highly the safety profile of this drug. Lipid formulations are taken selectively by the reticulo-endothelial system, and exhibit a highly localized enhanced antileishmanial action. There are three lipid formulations of amphotericin B: liposomal amphotericin B, amphotericin B lipid complex, and amphotericin B cholesterol dispersion. Currently, liposomal formulations of amphotericin B are the first treatment choice in southern Europe endemic countries as well as in other developed countries, because of their rapid and up to 100% cure rates with 3–5 days schemes, improved convenience for the patient, and reduction of health-care costs [27, 39, 40]. However, in poor countries even short courses of liposomal formulations are unaffordable, and the selection of antileishmanial treatment turns more to a question of cost than of efficacy or toxicity [6, 27]. The use of nanoparticles and microspheres for the delivery of conventional amphotericin B also increased its efficacy against experimental VL [41–43]. Similar results have been reported with the heat-induced reformulation of amphotericin B [44].

5. Miltefosine

Miltefosine (hexadecylphosphocholine) is the first orally administered drug for VL and the latest to enter the market. This agent is associated with high efficacy rates,
including cases unresponsive to antimonials [45, 46]. In a phase IV multicenter trial in India of 1132 adults and children with VL treated with miltefosine, cure rates were 82% per intention-to-treat analysis and 95% per protocol analysis [47]. In this study, 3% of patients developed adverse effects, mainly gastrointestinal toxicity, and elevated hepatic transaminases and creatinine [47]. So far, miltefosine is licenced in India, Germany, and Colombia. The scheme of miltefosine is 100 mg/kg/day for 28 days in adults weighing ≥50 kg, 50 mg/kg/day in adults <50 kg, and 2.5 mg/kg/day in children (maximum dose: 100 mg/day). Major concerns for the wide use of miltefosine include its teratogenic potential and its long half-life (approximately 150 hours) which may facilitate the emergence of resistance. Miltefosine is strictly forbidden in women of child-bearing age who may become pregnant up to two months following drug discontinuation. In India miltefosine is available over the counter, a fact that may expose this drug to misuse and emergence of resistance. Once generated, resistant parasites could spread rapidly, endangering the life span of miltefosine in a country where it is needed most.

The exact antileishmanial mechanism of miltefosine remains largely unknown. The intracellular accumulation of the drug appears to be the critical step for its action. The intracellular accumulation of miltefosine includes the following steps: binding to plasma membrane, internalization in the parasite cell (two proteins, the miltefosine transporter LdMT and its beta subunit LdRos3, are the most significant), and intracellular targeting and metabolism [48]. It has been found that miltefosine induces an apoptosis-like cell death in L. donovani, by producing numerous defects [48]. Miltefosine also induces several immunologic and inflammatory effects on macrophages. In animal models, miltefosine does not require T-cell-dependent immune mechanisms in order to act, indicating that this agent can be used in T-cell-deficient patients [12, 48]. Recently, it was found that miltefosine enhanced IFN-γ receptors and thus IFN-γ responsiveness in L. donovani-infected macrophages; in the same model, miltefosine induced an IL-12-dependent Th1 response and reversed the Th2 response to Th1 response [49]. Resistance to miltefosine may emerge easily during treatment due to single point mutations [50, 51]. Decrease in drug accumulation is the common denominator in all miltefosine resistant Leishmania lines studied to date, and this could be achieved through decreased uptake, increased efflux, faster metabolism, or altered plasma membrane permeability; the first two mechanisms have been already described in models of experimental miltefosine resistance [48, 50]. Two proteins, miltefosine transporter LdMT and its specific beta subunit LdRos3, form part of the miltefosine translocation machinery at the parasite plasma membrane, and are required for miltefosine uptake [48]. Experimental mutations at LdMT or LdRos3 rendered the parasites remarkably less sensitive to miltefosine, and this resistance persisted in vivo; cross-resistance with other antileishmanials was not detected [48, 50]. The overexpression of ABC transporters is another mechanism for acquisition of miltefosine resistance, through reduction of the drug intracellular accumulation [48, 52]. Recently, a novel flavonoid derivative was designed and it was shown that the use of suboptimal doses in order to overcome the overexpression of LtrMDR1 (a P-glucoprotein-like transporter belonging to the ATP-binding cassette superfamily) was associated with a four-fold increase of intracellular miltefosine accumulation in the resistant Leishmania lines [53]. Furthermore, modifications in lipid compositions of membranes and sterol biosynthesis have been detected in miltefosine-resistant L. donovani promastigotes [54]. Since membrane fluidity and permeability are influenced by lipid composition, their modification may affect drug-membrane interactions [54]. A case of a healthy patient with VL who relapsed 10 months after successful treatment with miltefosine for 28 days was reported recently [55].

6. Paromomycin

Paromomycin (aminosidine) is an aminoglycoside with antileishmanial activity. In a phase III study of VL in India, this drug was associated with 94.6% cure rates, similar to amphotericin B [56]. Adverse effects were more frequent in the paromomycin-treated group compared with the amphotericin B-treated group (6% versus 2%, resp.); paromomycin-related adverse effects included elevated hepatic transaminases, ototoxicity, and pain at injection-site [56]. Currently, paromomycin is under phase IV clinical trials. Paromomycin is inexpensive but requires daily intra-muscular injections for 21 days [6].

Paromomycin inhibits protein synthesis and modifies membrane fluidity and permeability. An in vitro study showed that following a 72-hour exposure to L. donovani promastigotes and amastigotes to paromomycin, the mitochondrial potential was decreased, which indicates that mitochondria are the targets of the drug [57]. In laboratory-derived resistant parasites developed through serial-passage increasing-drug concentrations, paromomycin uptake was decreased compared to the wild-type parasite, in association with inhibition of protein synthesis; no cross-resistance with other antimonial agents was detected [57]. Since paromomycin is an aminoglycoside, it is possible that resistance will emerge rapidly if used as monotherapy.

7. Combination Regimens

The rational for using combination regimens with different resistance mechanisms over monotherapy relies on the expected enhanced efficacy (through synergy or additive activity without drug interaction), shorter treatment duration, less toxicity, improved compliance, reduced likelihood of emergence of resistance, and reduced costs. A combination policy for VL is supported by the fact that antileishmanial drugs belong to different chemical classes. Recent studies have investigated this option. In a retrospective study conducted among Sudanese patients with VL, it was found that combination of sodium stibogluconate and paromomycin administered for 17 days was associated with higher cure and survival rates compared to sodium stibogluconate
monotherapy administered for 30 days (44%–86% lower odds of death in the combination group) [58]. Combinations of miltefosine with amphotericin B, paromomycin or pentavalent antimonials have been evaluated in an in vivo model and revealed that the combinations of miltefosine with amphotericin B or paromomycin were efficacious [59]. These preliminary data justified a recent study in Bihar, India, comparing 5 mg/kg of liposomal amphotericin B administered once (group A; 45 patients), 5 mg/kg of liposomal amphotericin B administered once plus miltefosine for either 10 days (group B; 46 patients) or 14 days (group C; 45 patients), 3.75 mg/kg of liposomal amphotericin B administered once plus miltefosine for 14 days (group D; 45 patients), and 5 mg/kg of liposomal amphotericin B administered once followed by miltefosine for 7 days (group E; 45 patients); in this study, similar final cure rates (91%–98%) were noted in all treatment groups [60]. These data indicate that a single dose of liposomal amphotericin B followed by 7–14 days of miltefosine is active against Indian VL [60]. In this study, all patients were treated in an outpatient setting. Large, randomized-controlled trials are required before adaptation of combination regimens.

Several combination regimens with investigational agents have been tested in vitro and in animal models [61]. The plant-derived immunostimulant agent picroliv has no antileishmanial activity, however when administered with half-dose miltefosine increases significantly the activity of the later [62]. The combination of verapamil (a calcium channel blocker) and diperoxovanadate (a potent antileishmanial agent) with sodium antimony gluconate reversed the in vitro antimonial resistance among clinical L. donovani isolates [63, 64]. Diperoxovanadate also demonstrated immunomodulating effects by increasing IFN and decreasing IL-10 [64]. These combinations deserve further testing in VL cases unresponsive to antimonials.

8. Strategies to Preserve the Efficacy of Currently Available Antileishmanials

In addition to intrinsic pharmacologic features, there is a number of human parameters that may favor the emergence and spread of leishmanial resistance. These include poor compliance, expensive treatment, availability of antileishmanial drugs over the counter, and limited access to health-care facilities for early diagnosis and treatment. Given the current situation of the widespread emergence of antimonial resistance in India, there is growing concern to preserve the efficacy of novel antileishmanials. Such a strategy should focus on the following axioms.

(1) Treatment of VL should be based on guidelines for prompt diagnosis, selection of first-line drugs, management of cases unresponsive to antimonials, and HIV-coinfected cases. A recent study of Indian VL cases revealed that a strategy of treatment with antimonials (first choice) or amphotericin B (second choice), based on culture and susceptibility results, compared with an empiric treatment strategy, was associated with higher cure rates (86.21% versus 35.71%), and reduced expenses, duration of hospitalization, and likely period of spread of parasites in the community [65].

(2) In order to enhance compliance, directly observed therapy for antileishmanials should be implemented, like in tuberculosis control programs.

(3) VL cases should be treated early in order to avoid further transmission of resistant parasites in the community.

(4) Distribution and clinical response of antileishmanials should be monitored.

(5) Antileishmanial treatment should be provided free-of-charge through the health-care system.

(6) The emergence and spread of antileishmanial resistance should be monitored.

(7) The efficacy and safety of combination regimens should be evaluated in large trials.

9. Conclusions

The control of VL globally is challenged by the widespread emergence of antimonial resistance in India. The last decade new formulations of conventional antileishmanial drugs as well as new agents became available. The wide use of the oral agent miltefosine was hampered by the potential for teratogenicity and emergence of resistance. Combination regimens should be evaluated in large trials. The last years several mechanisms of in field antileishmanial resistance were identified. Understanding their molecular and biochemical characteristics will lead the design of new drugs and also the molecular surveillance of resistance. In order not to jeopardize the life span of available antileishmanials, their delivery, clinical response, and resistance should be monitored. Overall the development of antileishmanials has been generally slow; new drugs are needed.

Author’s Statement

The findings and opinions in this review are those of the author and do not necessarily represent those of the Hellenic Center for Disease Control and Prevention.

References

[1] World Health Organization, “Leishmaniasis: burden of disease,” August 2009, http://www.who.int/leishmaniasis/burden/en.

[2] H. C. Maltezou, C. Siafas, M. Mavrikou, et al., “Visceral leishmaniasis during childhood in Southern Greece,” Clinical Infectious Diseases, vol. 31, no. 5, pp. 1139–1143, 2000.

[3] P. Minodier, R. Piarroux, J.-M. Garnier, D. Uanal, H. Perri mond, and H. Dumon, “Pediatric visceral leishmaniasis in Southern France,” Pediatric Infectious Disease Journal, vol. 17, no. 8, pp. 701–704, 1998.

[4] M.-E. Raguenaud, A. Jansson, V. Vanlambergh, et al., “Epidemiology and clinical features of patients with visceral leishmaniasis treated by an MSF clinic in Bakool Region,
S. Sundar, J. Chakravarty, V. K. Rai, et al., “Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions,” *Clinical Infectious Diseases*, vol. 45, no. 5, pp. 556–561, 2007.

[7] J. Alvar, P. Aparicio, A. Asfella, et al., “The relationship between leishmaniasis and AIDS: the second 10 years,” *Clinical Microbiology Reviews*, vol. 21, no. 2, pp. 334–359, 2008.

[8] S. Saha, S. Mondal, A. Banerjee, J. Ghose, S. Bhowmick, and N. Ali, “Immune responses in kala-azar,” *Indian Journal of Medical Research*, vol. 123, no. 3, pp. 245–266, 2006.

[9] R. C. Jochim and C. Teixeira, “Leishmania commandeers the cell’s endosomes to escape phagolysosomes,” *Trends in Parasitology*, vol. 25, no. 4, pp. 145–147, 2009.

[10] E. McFarlane, C. Perez, M. Charmoy, et al., “Neutrophils contribute to development of a protective immune response during onset of infection with *Leishmania donovani*,” *Infection and Immunity*, vol. 76, no. 2, pp. 532–541, 2008.

[11] L. Lachaud, N. Bourgeois, M. Plourde, P. Leprohon, P. Bastien, and M. Ouellette, “Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and *Leishmania infantum*,” *Clinical Infectious Diseases*, vol. 48, no. 2, pp. e16–e22, 2009.

[12] N. Marques, R. Sá, F. Coelho, J. Oliveira, J. Saraiva Da Cunha, and A. Melco-Silvestre, “Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients,” *Scandinavian Journal of Infectious Diseases*, vol. 40, no. 6-7, pp. 523–526, 2008.

[13] S. Nylen and D. Sacks, “Interleukin-10 and the pathogenesis of human visceral leishmaniasis,” *Trends in Immunology*, vol. 28, no. 9, pp. 378–384, 2007.

[14] H. W. Murray, C. M. Lu, S. Mauze, et al., “Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy,” *Infection and Immunity*, vol. 70, no. 11, pp. 6284–6293, 2002.

[15] N. Rolao, S. Cortes, S. Gomes-Pereira, and L. Campino, “*Leishmania infantum*: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice,” *Experimental Parasitology*, vol. 115, no. 3, pp. 270–276, 2007.

[16] J. Alexander, K. Christine-Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher, “Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis,” *European Journal of Immunology*, vol. 30, no. 10, pp. 2935–2943, 2000.

[17] R. Basu, S. Bhaumik, A. K. Haldar, et al., “Hybrid cell vaccination resolves *Leishmania donovani* infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13,” *Infection and Immunity*, vol. 75, no. 12, pp. 5956–5966, 2007.

[18] H. Kothari, P. Kumar, S. Sundar, and N. Singh, “Possibility of membrane modification as a mechanism of antigenic resistance in *Leishmania donovani*,” *Parasitology International*, vol. 56, no. 1, pp. 77–80, 2007.

[19] K. C. Carter, S. Hutchison, F. L. Henriquez, et al., “Resistance of *Leishmania donovani* to sodium stibogluconate is related to the expression of host and parasite γ-glutamylcysteine synthetase,” *Antimicrobial Agents and Chemotherapy*, vol. 50, no. 1, pp. 88–95, 2006.

[20] N. Singh, “Drug resistance mechanisms in clinical isolates of *Leishmania donovani*,” *Indian Journal of Medical Research*, vol. 123, no. 3, pp. 411–422, 2006.

[21] K. Choudhury, D. Zander, M. Kube, R. Reinhardt, and J. Clos, “Identification of a *Leishmania infantum* gene mediating resistance to miltefosine and SB1,” *International Journal for Parasitology*, vol. 38, no. 12, pp. 1411–1423, 2008.

[22] S. Wylie, T. J. Vickers, and A. H. Fairlamb, “Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials,” *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 4, pp. 1539–1565, 2008.

[23] S. Sundar, D. K. More, M. K. Singh, et al., “Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic,” *Clinical Infectious Diseases*, vol. 31, no. 4, pp. 1104–1107, 2000.

[24] R. Singh, D. Kumar, V. Ramesh, N. S. Negi, S. Singh, and P. Salotra, “Visceral leishmaniasis, or Kala Azar (KA): high incidence of refractoriness to antimony is contributed by anthropogenic transmission via post-KA dermal leishmaniasis,” *Journal of Infectious Diseases*, vol. 194, no. 3, pp. 302–306, 2006.

[25] S. Sundar, B. B. Thakur, A. K. Tandon, et al., “Clinicoparasitological study of drug resistance in Indian kala-azar,” *British Medical Journal*, vol. 308, no. 6924, p. 307, 1994.

[26] M. G. Abdol, W. M. Elamin, E. A. G. Khalil, and M. M. Mukhtar, “Antimony-resistant *Leishmania donovani* in eastern Sudan: incidence and in vitro correlation,” *Eastern Mediterranean Health Journal*, vol. 9, no. 4, pp. 837–843, 2003.

[27] L. Gradoni, K. Soteriadou, H. Louzir, et al., “Drug regimens for visceral leishmaniasis in Mediterranean countries,” *Tropical Medicine and International Health*, vol. 13, no. 10, pp. 1272–1276, 2008.

[28] S. Decuypere, S. Rijal, V. Yardley, et al., “Gene expression analysis of the mechanism of natural SB(V) resistance in *Leishmania donovani* isolates from Nepal,” *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 11, pp. 4616–4621, 2005.

[29] A. H. Sharief, E. A. Gasim-Khalil, T. G. Theander, A. Kharaizmi, S. A. Omer, and M. E. Ibrahim, “*Leishmania donovani*: an in vitro study of antimony-resistant amphotericin B-sensitive isolates,” *Experimental Parasitology*, vol. 114, no. 4, pp. 247–252, 2007.

[30] K. Choudhury, D. Zander, M. Kube, R. Reinhardt, and J. Clos, “Identification of a *Leishmania infantum* gene mediating resistance to miltefosine and SB1,” *International Journal for Parasitology*, vol. 38, no. 12, pp. 1411–1423, 2008.

[31] A. Mukherjee, P. K. Padmanaban, S. Singh, et al., “Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of *Leishmania donovani*,” *Journal of Antimicrobial Chemotherapy*, vol. 59, no. 2, pp. 204–211, 2007.

[32] F. Cortés-Selva, I. A. Jiménez, F. Muñoz-Martínez, et al., “Dihidro-β-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in the protozoan parasite *Leishmania*,” *Current Pharmaceutical Design*, vol. 11, no. 24, pp. 3125–3159, 2005.

[33] M. K. Mittal, S. Rai, A. Ravinger, S. Gupta, S. Sundar, and N. Goyal, “Characterization of natural antimony resistance in *Leishmania donovani* isolates,” *American Journal of Tropical Medicine and Hygiene*, vol. 76, no. 4, pp. 681–688, 2007.

[34] G. Mandal, A. Sarkar, P. Saha, N. Singh, S. Sundar, and M. Chatterjee, “Functionality of drug efflux pumps in antimonial resistant *Leishmania donovani* field isolates,” *Indian Journal of Biochemistry and Biophysics*, vol. 46, no. 1, pp. 86–92, 2009.
[35] J. M. Basu, A. Mookerjee, R. Banerjee, et al., “Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection,” *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 3, pp. 1080–1093, 2008.

[36] I. L. Wong, K.-F. Chan, B. A. Burkett, et al., “Flavonoid dimers as bivalent modulators for pentamidine and sodium stibogluconate resistance in Leishmania,” *Antimicrobial Agents and Chemotherapy*, vol. 51, no. 3, pp. 930–940, 2007.

[37] T. Laurent, S. Rijal, V. Yardley, et al., “Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal,” *Infection, Genetics and Evolution*, vol. 7, no. 2, pp. 206–212, 2007.

[38] A. Kumar, V. R. Boggula, S. Sundar, A. K. Shasany, and A. Dube, “Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP),” *Acta Tropica*, vol. 110, no. 1, pp. 80–85, 2009.

[39] C. P. Thakur, A. K. Pandey, G. P. Sinha, S. Roy, K. Bebbehani, and P. Olliaro, “Comparison of three treatment regimens with liposomal amphotericin B (Ambisome) for visceral leishmaniasis in India: a randomized dose-finding study,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 90, no. 3, pp. 319–322, 1996.

[40] S. Sundar, T. K. Jha, C. P. Thakur, M. Mishra, R. V. Singh, and R. Buffle, “Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study,” *American Journal of Tropical Medicine and Hygiene*, vol. 66, no. 2, pp. 143–146, 2002.

[41] K. D. Manandhar, T. P. Yadav, V. K. Prajapati, et al., “Antileishmanial activity of nano-amphotericin B deoxycholate,” *Journal of Antimicrobial Chemotherapy*, vol. 62, no. 2, pp. 376–380, 2008.

[42] L. Ordóñez-Gutiérrez, R. Espada-Fernández, M. A. Dea-Ayuela, J. J. Torrado, F. Bolás-Fernandez, and J. M. Alunda, “In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum,” *International Journal of Antimicrobial Agents*, vol. 30, no. 4, pp. 325–329, 2007.

[43] J. J. Torrado, R. Espada, M. P. Ballesteros, and J. Torrado-Santiago, “Amphotericin B formulations and drug targeting,” *Journal of Pharmaceutical Sciences*, vol. 97, no. 7, pp. 2405–2425, 2008.

[44] S. Gupta, A. Dube, and S. P. Vyas, “Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis,” *Journal of Drug Targeting*, vol. 15, no. 6, pp. 437–444, 2007.

[45] A. Dube, N. Singh, S. Sundar, and N. Singh, “Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models,” *Parasitology Research*, vol. 96, no. 4, pp. 216–223, 2005.

[46] K. Ritmeijer, A. Dejenie, Y. Assefa, et al., “A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection,” *Clinical Infectious Diseases*, vol. 43, no. 3, pp. 357–364, 2006.

[47] S. K. Bhattacharya, P. K. Sinha, S. Sundar, et al., “Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis,” *Journal of Infectious Diseases*, vol. 196, no. 4, pp. 591–598, 2007.

[48] F. J. Pérez-Victoria, M. P. Sanchez-Canete, K. Seifert, et al., “Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use,” *Drug Resistance Updates*, vol. 9, no. 1–2, pp. 26–39, 2006.

[49] P. Wadhone, M. Maiti, R. Agarwal, V. Kamat, S. Martin, and B. Saha, “Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response,” *Journal of Immunology*, vol. 182, no. 11, pp. 7146–7154, 2009.

[50] K. Seifert, F. J. Pérez-Victoria, M. Stettler, et al., “Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo,” *International Journal of Antimicrobial Agents*, vol. 30, no. 3, pp. 229–235, 2007.

[51] K. Seifert, S. Matu, F. J. Pérez-Victoria, S. Castanys, F. Gamarro, and S. L. Croft, “Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine),” *International Journal of Antimicrobial Agents*, vol. 22, no. 4, pp. 380–387, 2003.

[52] S. Castanys-Munoz, J. M. Pérez-Victoria, F. Gamarro, and S. Castanys, “Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement,” *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 10, pp. 3573–3579, 2008.

[53] J. M. Pérez-Victoria, F. Cortes-Selva, A. Parodi-Talice, et al., “Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux,” *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 7, pp. 2677–2686, 2005.

[54] M. Rakotomanga, M. Saint-Pierre-Chazalet, and P. M. Loiseau, “Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions,” *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 7, pp. 2677–2686, 2005.

[55] B. D. Pandey, K. Pandey, O. Kaneko, T. Yanagi, and K. Hirayama, “Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient,” *American Journal of Tropical Medicine and Hygiene*, vol. 80, no. 4, pp. 580–582, 2009.

[56] S. Sundar, T. K. Jha, C. P. Thakur, P. K. Sinha, and S. K. Bhattacharya, “Injectable paromomycin for visceral leishmaniasis in India,” *New England Journal of Medicine*, vol. 356, no. 25, pp. 2571–2581, 2007.

[57] A. Jhingran, B. Chawla, S. Saxena, M. P. Barrett, and R. Madhubala, “Paromomycin: uptake and resistance in Leishmania donovani,” *Molecular and Biochemical Parasitology*, vol. 164, no. 2, pp. 111–117, 2009.

[58] Y. Melaku, S. M. Collin, F. Gatluak, K. Ritmeijer, and R. N. Davidson, “Treatment of kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy,” *American Journal of Tropical Medicine and Hygiene*, vol. 77, no. 1, pp. 89–94, 2007.

[59] K. Seifert and S. L. Croft, “In vitro and in vivo interactions between miltefosine and other antileishmanial drugs,” *Antimicrobial Agents and Chemotherapy*, vol. 50, no. 1, pp. 73–79, 2006.

[60] S. Sundar, M. Rai, J. Chakravarty, et al., “New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine,” *Clinical Infectious Diseases*, vol. 47, no. 8, pp. 1000–1006, 2008.

[61] H. C. Matlezou, “Visceral leishmaniasis: advances in treatment,” *Recent Patents on Anti-Infective Drug Discovery*, vol. 3, no. 3, pp. 192–198, 2008.
[62] S. Gupta, S. C. Ramesh, and V. M. Srivastava, “Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis,” *Acta Tropica*, vol. 94, no. 1, pp. 41–47, 2005.

[63] R. Valiathan, M. L. Dubey, R. C. Mahajan, and N. Malla, “*Leishmania donovani*: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate,” *Experimental Parasitology*, vol. 114, no. 2, pp. 103–108, 2006.

[64] A. K. Haldar, S. Banerjee, K. Naskar, D. Kalita, N. S. Islam, and S. Roy, “Sub-optimal dose of sodium antimony gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant *Leishmania donovani* by expanding antileishmanial T-cell repertoire and increasing IFN-γ to IL-10 ratio,” *Experimental Parasitology*, vol. 122, no. 2, pp. 145–154, 2009.

[65] C. P. Thakur, S. Thakur, S. Narayan, and A. Sinha, “Comparison of treatment regimens of kala-azar based on culture and sensitivity amastigotes to sodium antimony gluconate,” *Indian Journal of Medical Research*, vol. 127, no. 6, pp. 582–588, 2008.